1. Home
  2. SCHL vs ALT Comparison

SCHL vs ALT Comparison

Compare SCHL & ALT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Scholastic Corporation

SCHL

Scholastic Corporation

N/A

Current Price

$36.13

Market Cap

672.6M

ML Signal

N/A

Logo Altimmune Inc.

ALT

Altimmune Inc.

N/A

Current Price

$2.78

Market Cap

573.8M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
SCHL
ALT
Founded
1920
1997
Country
United States
United States
Employees
N/A
N/A
Industry
Books
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
672.6M
573.8M
IPO Year
1995
2005

Fundamental Metrics

Financial Performance
Metric
SCHL
ALT
Price
$36.13
$2.78
Analyst Decision
Strong Buy
Analyst Count
0
10
Target Price
N/A
★ $17.11
AVG Volume (30 Days)
381.9K
★ 3.1M
Earning Date
09-24-2026
11-05-2026
Dividend Yield
★ 2.84%
N/A
EPS Growth
★ 3442.86
25.37
EPS
N/A
★ N/A
Revenue
★ $1,487,100,000.00
$41,000.00
Revenue This Year
$2.14
N/A
Revenue Next Year
$3.42
N/A
P/E Ratio
N/A
★ N/A
Revenue Growth
N/A
★ 105.00
52 Week Low
$26.38
$2.56
52 Week High
$48.07
$6.44

Technical Indicators

Market Signals
Indicator
SCHL
ALT
Relative Strength Index (RSI) 43.84 34.73
Support Level $32.81 $2.80
Resistance Level $35.89 $3.35
Average True Range (ATR) 1.14 0.12
MACD 0.25 -0.06
Stochastic Oscillator 75.14 3.28

Price Performance

Historical Comparison
SCHL
ALT

About SCHL Scholastic Corporation

Scholastic Corp is a publisher and distributor of children's books, a provider of print and digital instructional materials for grades pre-kindergarten (pre-K) to grade 12 and a producer of entertaining literary and educational children's media. The company creates quality print, digital and audio books, learning materials and programs, classroom magazines and other products that, in combination, offer children, families and educators engaging and comprehensive solutions to support children's learning and reading both at home and at school. It categorizes its businesses into four reportable segments: Children's Book Publishing and Distribution; Education; Entertainment; and International. It derives the majority of revenue from Children's Book Publishing and Distribution segment.

About ALT Altimmune Inc.

Altimmune Inc is a late clinical-stage biopharmaceutical company developing therapies for patients with serious liver diseases. The Company's key candidate, pemvidutide, is a dual-action therapy targeting both glucagon and GLP-1 receptors in a balanced 1:1 ratio in development for the treatment of metabolic dysfunction-associated steatohepatitis (MASH), alcohol use disorder (AUD), and alcohol-associated liver disease (ALD). The company also plans to pursue additional indications for pemvidutide that leverage the differentiated clinical profile of pemvidutide.

Share on Social Networks: